Search

everythinglearnresearchcommunity

for

Search:↓

Vitamin D and D3 are the same. Treatments discussed include Minoxidil, finasteride, and RU58841.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The conversation discusses whether creatine is safe to use with finasteride for hair loss treatment. It suggests consulting a doctor before adjusting finasteride dosage.

A user is waiting for pyrilutamide delivery and is seeking reviews, especially regarding side effects. No reviews have been mentioned in the conversation.

Treatments for hair loss, including the experiences of topical finasteride and oral dutasteride. It also discusses Pyrilutamide, 0.025% topical concentration, Minoxidil, RU58841, and 1% finasteride gel dosage.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

Dutasteride and finasteride for hair loss, with dissatisfaction expressed about dutasteride and consideration of switching back to finasteride. Users share varied experiences, noting individual responses to treatments differ.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The user has been using 1mg oral finasteride daily for four years, experiencing significant hair regrowth and increased testosterone levels without negative side effects. They advise patience and monitoring for side effects, noting that their hair continues to improve with this treatment.

User Solid_Repeat5382 shared their experience with Pyrilutamide for hair loss, which initially reduced shedding but later lost effectiveness. They plan to switch back to RU58841 and finasteride, while continuing minoxidil and dermapen treatments.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

The user has been using oral Dutasteride, RU58841, and Minoxidil for three years without success and is considering adding topical Finasteride or Dutasteride to target DHT both locally and systemically. Other users suggest sticking to a consistent treatment plan, exploring different combinations, and considering other factors like potential misdiagnosis or inconsistent medication use.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.

The user switched from finasteride to dutasteride due to side effects and is experiencing fewer side effects with dutasteride, though some scalp itching has occurred. Blood tests show elevated testosterone and estrogen, low DHT, and normal liver and cholesterol levels, leading the user to feel confident in the long-term benefits of dutasteride for hair regrowth.

GHK-Cu and Acetyl Tetrapeptide-3 are ineffective for hair regrowth according to user experiences. Effective treatments mentioned are finasteride, dutasteride, and minoxidil.

The user's experience taking Pyrilutamide, a drug for hair loss treatment, and their use of it in combination with other treatments such as Minoxidil, Finasteride and RU58841. They have experienced positive results so far with no major side effects.

A person experienced severe sexual side effects, including loss of libido and erectile dysfunction, after using finasteride and dutasteride for hair loss. They stopped the medications and sought advice, but recovery was slow and uncertain.

The user switched from finasteride to dutasteride and oral minoxidil after experiencing side effects and worsening hair loss, which improved their condition. Dutasteride was preferred due to fewer side effects and better results compared to finasteride.

Mixing Dutasteride with MCT oil may improve absorption due to its fat-soluble nature. Users suggest taking it with whole milk or using oil-based capsules for better effectiveness.